** Shares of drug developer Plus Therapeutics PSTV.O more than double to 38 cents
** Co says the U.S. FDA has cleared its application to begin human trials for its experimental brain cancer therapy
** The trial is funded by a $3 million research grant from the U.S. Department of Defense, co says
** The early-stage trial is aimed to determine the maximum tolerated dose safety and tolerability of the therapy called Reyobiq in pediatric patients aged six to 21 years
** The company is testing the therapy to treat aggressive brain tumors called high-grade glioma and ependymoma
** Including session moves, stock down 68.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.